Author Question: Which of the following deficiencies prolongs the PTT but does not lead to abnormal bleeding? a. ... (Read 35 times)

tuffie

  • Hero Member
  • *****
  • Posts: 534
Which of the following deficiencies prolongs the PTT but does not lead to abnormal bleeding?
 
  a. Factor V
  b. Factor VIII
  c. Factor XI
  d. Factor XII

Question 2

Why is it important to monitor patients who are receiving anticoagulant therapy?
 
  a. Drugs are expensive.
  b. Prophylactic and therapeutic dosage ranges are unknown.
  c. Patients commonly abuse these drugs.
  d. Clinical consequences for overdosing or underdosing are significant.



Kimmy

  • Sr. Member
  • ****
  • Posts: 342
Answer to Question 1

ANS: D
A deficiency of factor XII prolongs the PTT. However, patients with this deficiency do not have abnormal bleeding.

Answer to Question 2

ANS: D
The clinical consequences for incorrect dosage of anticoagulant drugs are significant. Overanticoagulation can lead to serious bleeding that may even require a visit to the emergency department. Underanticoagulatio n can lead to further thrombotic events (presumably the reason the patient is on the drug). The prophylactic and therapeutic ranges for the drugs are known and are narrow, which is another reason they must be monitored. Some of the drugs are expensive, but others are not.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
 

Did you know?

Fungal nail infections account for up to 30% of all skin infections. They affect 5% of the general population—mostly people over the age of 70.

Did you know?

The first documented use of surgical anesthesia in the United States was in Connecticut in 1844.

Did you know?

Alcohol acts as a diuretic. Eight ounces of water is needed to metabolize just 1 ounce of alcohol.

Did you know?

More than 2,500 barbiturates have been synthesized. At the height of their popularity, about 50 were marketed for human use.

Did you know?

For high blood pressure (hypertension), a new class of drug, called a vasopeptidase blocker (inhibitor), has been developed. It decreases blood pressure by simultaneously dilating the peripheral arteries and increasing the body's loss of salt.

For a complete list of videos, visit our video library